A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Required: CD20 expression (expected to express the cd20 antigen)

Must have received: systemic therapy

Dose Escalation: relapsed after or failed to respond to at least two prior lines of systemic therapy. Dose Expansion: FL Grades 1-3a must have relapsed after or failed to respond to at least one prior line of systemic therapy and must require systemic therapy. DLBCL/transformed FL must have relapsed after or failed to respond to at least one prior systemic treatment regimen.

Cannot have received: cereblon (CRBN)-modulating drug (lenalidomide, avadomide, CC-122, pomalidomide)

prior therapy with cereblon (CRBN)-modulating drug (e.g., lenalidomide, avadomide/CC-122, pomalidomide) </= 4 weeks prior to starting CC-220 and/or CC-99282

Cannot have received: CD20/CD3-directed bispecific antibody (mosunetuzumab, glofitamab)

mosunetuzumab, glofitamab, or other CD20/CD3-directed bispecific antibodies

Cannot have received: allogenic stem cell therapy

allogenic stem cell therapy (SCT)

Cannot have received: solid organ transplantation

solid organ transplantation

Cannot have received: radiotherapy

radiotherapy within 2 weeks

Cannot have received: autologous stem cell transplant

autologous SCT within 100 days

Cannot have received: CAR-T cell therapy

chimeric antigen receptor (CAR) T-cell therapy within 30 days

Cannot have received: monoclonal antibody

prior anti-lymphoma treatment with monoclonal antibodies or antibody-drug conjugates within 4 weeks

Cannot have received: antibody-drug conjugate

prior anti-lymphoma treatment with monoclonal antibodies or antibody-drug conjugates within 4 weeks

Cannot have received: radioimmunoconjugate

use of radioimmunoconjugates within 12 weeks

Cannot have received: systemic immunosuppressive medication

systemic immunosuppressive medications within 2 weeks

Cannot have received: anti-cancer therapy

any other anti-cancer therapy, whether investigational or approved, including but not limited to chemotherapy, within 4 weeks or 5 half-lives of the drug, whichever is shorter